Metalloproteinases and neurovascular injury;Metaloproteasas y lesión neurovascular

Neurologia

Volumn 19, Issue 6, 2004, Pages 312-320

  Castillo, José ^a   Leira, R ^a   Blanco, M ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Cerebral hemorrhage; Matrix metalloproteirase; MMP 9; Neuroinflarnaci n; Stroke; Thrombolysis

Indexed keywords

COLLAGENASE; COLLAGENASE 1; COLLAGENASE 2; COLLAGENASE 3; COLLAGENASE 4; CYSTEINE PROTEINASE; GELATINASE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRILYSIN 1; MATRILYSIN 2; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 18; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 26; NEUTROPHIL COLLAGENASE; SERINE PROTEINASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UROKINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANEURYSM; ARTHRITIS; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BRAIN EDEMA; BRAIN HEMORRHAGE; CANCER; CEREBROVASCULAR ACCIDENT; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; REVIEW; STROKE;

CEREBROVASCULAR DISORDERS; HUMANS; METALLOPROTEASES;

EID: 3343015548     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003;200:423-8.
2. Ottani V, Raspanti M, Ruggeri A. Collagen structure and functional implications. Micron 2001;32:251-60.
3. Kresse H, Schonherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 2001;189:266-74.
4. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200:448-64.
5. Visse R, Nagase H. Matrix metalloproteinase and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Cir Res 2003;92:827-39.
6. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
7. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Cir Res 2002;90:251-62.
8. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation. Part II. Circulation 2003;108:2041-8.
9. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMP are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998;29:2189-95.
10. Rosenberg GA. Matrix metalloproteinases in multiple sclerosis: is it time for a treatment trial? Ann Neurol 2001;50:431-3.
11. Rosenberg GA, Sullivan N, Isiri MM. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 2001;32:1162-8.
12. Woessner JF. The matrix metalloproteinase familiy. En: Parks WC, Mechan RP, editores. Matrix metalloproteinases. San Diego: Academic Press, 1998; p. 1-13.
13. Patterson ML, Atkinson SJ, Knäuper U, Murphy G. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett 2001;503:158-62.
14. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digest intersticial collagens and other extracellular matrix macromolecules. J Biol Chem 1997;272:2446-51.
15. Moro MA, Hurtado O, Cárdenas A, Romera C, Madrigal JL, Fernández-Tomé P, et al. Expression and function of TACE (TNF-α converting enzyme) in the central nervous system. Neurosignals 2003;12:53-8.
16. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002;39:279-91.
17. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem Hoppe Seyler 1997;378:151-60.
18. Fini ME, Cook JR, Mohan R, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression. En: Parks WC, Mecham RP, editores. Matrix metalloproteinases. San Diego: Academic Press, 1998; p. 299-356.
19. Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, et al. Cytokine and chedmokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 1997;158:2327-33.
20. Stearus ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999;1:189-96.
21. Leppert D, Lindberg RLP, Kappost L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Rev 2001;36:249-57.
22. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
23. Knäuper V, Murphy G. Membrane-type matrix metalloproteinases and cell surcafe-associated activation cascades for matrix metalloproteinases. En: Parks WC, Mecham RP, editores. Matrix metalloproteinases. San Diego: Academic Press 1998; p. 199-218.
24. Gómez DE, Alonso DF, Yoshiji H, Thorgeirsson VP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
25. Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 2000;275:26411-5.
26. Sinha S, Frishman WH. Matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target. J Clin Pharmacol 1998;38:1077-88.
27. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases and atherosclerosis. Therapeutic aspects. Ann Biol Clin (Paris) 2003;61:147-58.
28. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
29. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Smidt A, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:283-8.
30. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-75.
31. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, et al. Enhanced expression of MMP-7 TIMP and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 1997;94:590-8.
32. Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol 1998;44:592-600.
33. Gasche Y, Fujimura Y, Copin J, Kawase M, Masengale J, Chan PH. Early appearance of activated matriz metalloproteinse-9 after focal cerebral ischemia in mice: posible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999;19:1020-8.
34. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPS are associated with blood-brain barrier opening after reperfusion in rats. Stroke 1998;29:2189-5.
35. Asashi M, Asashi K, Jung J, del Zoppo G, Fini ME, Lo EH. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000;20:11681-9.
36. Hamann GF, del Zoppo GJ, von Kummer R. Hemorrhagic transformation of cerebral infarction: possible mechanisms. Thromb Haemost 1999;82(Suppl 1):92-4.
37. Rosenberg GA. Ischemia brain edema. Prog Cardiovasc Dis 1999;42:209-16.
38. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activitics in human brain focal ischemia. Neurosci Lett 1997;238:53-6.
39. Dȧvalos A, Castillo J, Leira R, Serena J, Aneiros A, Castellanos M. Metalloproteinase-9 (MMP-9), early CT signs of cerebral ischemia and high blood pressure in acute stroke. Cerebrovasc Dis 2001;11(Suppl 4):118.
40. Montaner J, Alvárez-Sabin J, Molina C, Anglés A, Abilleira S, Arenillas J, et al. Matrix metalloproteinase expression alter human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001;32:1759-66.
41. Castillo J, Rodriguez I. Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004;17(Suppl 1):7-18.
42. Montaner J, Alvárez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, et al. Matrix metalloproteinase (MMP-9) expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001;32:2762-7.
43. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, et al. Plasma metalloprototeinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34:40-6.
44. Castillo J, Serena J, Leira R, Castellanos M, Aneiros A, Dávalos A. Molecular markers of malignant middle cerebral artery infarction. Cerebrovasc Dis 2002;13(Suppl 3):59.
45. Castellanos M, Leira R, Serena J, Blanco M, Silva Y, Dávalos A, et al. Cellular fibronectine and endothelial injury in acute ischemic stroke. Stroke 2003;34:269.
46. Dávalos A, Castellanos M, Leira R, Pedraza S, Silva Y, Blanco M, et al. High plasma levels of cellular fibronectine predict hemorrhagic transformation after tPA treatment in acute stroke. Stroke 2003;34:247.
47. Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997;48:921-6.
48. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000;31:3034-40.
49. Power C, Henry S, Del Bigio MR, Larsen PH. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003;53:731-42.
50. Castillo J, Davalos A, Álvarez-Sabin J, Pumar JM, Leira R, Silva Y, et al. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology 2002;58:624-9.
51. Abilleira S, Montaner J, Molina C, Monasterio J, Castillo J, Álvarez-Sabin J. Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 2003;99:65-70.
52. Dávalos A, Álvarez-Sabin J, Kase C, Leira R, Silva Y, Montaner J, et al. Serum metalloproteinase-9 concentrations and brain injury in intracerebral hemorrhage. Cerebrovasc Dis 2002;13(Suppl 3):43.
53. Silva Y, Leira R, López J, Castellanos M, Blanco M, Serena J, et al. Early growth of intracerebral hemorrhage is associated with molecular signatures of vascular injury. Stroke 2003;34:242.
54. NINDs rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
55. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al, Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Stroke Study (ECASS). JAMA 1995;274:1017-25.
56. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Less KR, et al, for the MAST-E Group. Hemorrhagic transformations in acute stroke: the MAST-E study. Stroke 1999;130:1326-32.
57. NINDs rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous TPA therapy for ischemic stroke. Stroke 1997;28:2109-18.
58. Larrue V, von Kummer R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European- australiasian acute stroke study (ECASS II). Stroke 2001;32:438-41.
59. Lapchack P, Chapman D, Zivin J. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 200;31:3034-40.
60. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002;33:831-83.
61. Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinased inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003;34:2025-30.
62. Montaner J, Molina C, Monasterio J, Abilleira S, Arenillas J, Ribó M, et al. Matriz metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603.
63. Berger C, Fiorelli M, Stinert T, Schabitz WR, Bozzao L, Bluhmki E, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001;32:1330-5.
64. Heo JH, Kim SH, Lee KY, Kim EH, Chu CK, Nam JM. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003;34:48-50.
65. Cannon CP. Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 1999;34:1359-402.
66. Jurasz P, Chung AWY, Radomski A, Radomski MW. Nonremodeling properties of matrix metalloproteinases: the platelet connection. Circ Res 2002;90:1041-3.
67. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997;386:616-9.
68. Zhang ZG, Zhang L, Tsang W, Goussev A, Powers C, Ho KL, et al. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res 2001;912:181-94.
69. Asashi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001;21:7724-32.
70. Montaner J, Fernández-Cadenas I, Molina C, Monasterio J, Arenillas J, Ribó M, et al. Safety profile of tissue plasminogen activator treatment among stroke patients carring a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke 2003;34:2851-5.